Skip to main content

Advertisement

Table 6 Timeline of lymphatic filariasis programme activities in American Samoa, 1999–2011

From: Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration

Year Activity Survey population size Age group Prevalence (% antigenemia, ICT) MDA coverage (% total population treated)
1999 Nationwide mapping (convenience survey) [3] 3018 (18 villages) All 16.5  
2000 MDA [9]     19
2001 MDA [9]     51
2001 Sentinel survey [10] 1024 (4 villages) All 11.52  
2002 MDA [9]     49
2003 Drug distributor evaluation Community KAP survey Programme modifications [9]     
2003 MDA [9]     71
2003 Drug distributor evaluation Church leader survey Programme modifications [9]     
2003 Sentinel survey [10] 917 (4 villages) All 13.74  
2004 MDA [9]     65
2004 Drug coverage survey [9]     86
2005 MDA [9]     67
2006 MDA [9]     70
2006 Sentinel survey [10] 1371 (4 villages) All 0.95  
2006 Purposeful survey [11] 569 (3 villages) >5 years 4.22  
2007 Random household C-survey (spatial sampling design) 1881 (national) All 2.29  
2010 Random household survey (spatial sampling design) [15] 807 (national) ≥18 years 3.2 (Og4C3 antigen ELISA)  
2011 TAS [18] 949 6–7 years 0.21  
  1. ELISA enzyme-linked immunosorbent assay, ICT immunochromatographic card test, KAP knowledge, attitudes, practices, MDA mass drug administration, TAS transmission assessment survey